OBJECTIVE: To investigate the efficacy and safety of single-pill amlodipine/atorvastatin therapy for the simultaneous treatment of hypertension (HTN) and dyslipidemia in African Americans. PATIENTS AND METHODS: Conducted between July 19, 2004, and August 9, 2005, the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid End Points trial was a 20-week, open-label, noncomparative, multicenter trial of the efficacy and safety of single-pill amlodipine/atorvastatin in controlling elevated blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) in African Americans with concomitant HTN and dyslipidemia and either no additional risk factors, 1 or more cardiovascular risk factors, or coronary heart disease or a risk equivalent. Eight dosage strengths of single-pill amlodipine/atorvastatin were flexibly titrated. The primary efficacy assessment of the main trial was the percentage of patients who attained the LDL-C treatment goals of both the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National Cholesterol Education Program Adult Treatment Panel III. RESULTS: Of the 1170 African American patients screened, 501 were enrolled in the study and 499 received drug therapy. At end point, 236 (48.3%) of 489 patients reached both their BP and LDLC goals (vs 4 [0.8%] of 484 at baseline); 280 (56.8%) of 493 reached BP goals (vs 7 [1.4%] of 494 at baseline); and 361 (73.7%) of 490 reached LDL-C goals (vs 138 [28.5%] of 484 at baseline). Among the 499 patients receivingdrug therapy, common treatment-related adverse events were peripheral edema (17 patients [3.4%]), headache (11 [2.2%]), myalgia (11 [2.2%]), and constipation (10 [2.0%]). CONCLUSION:Single-pill amlodipine/atorvastatin therapy was well tolerated and effectively targeted HTN and dyslipidemia in this population of African Americans who were at risk of cardiovascular disease.
RCT Entities:
OBJECTIVE: To investigate the efficacy and safety of single-pill amlodipine/atorvastatin therapy for the simultaneous treatment of hypertension (HTN) and dyslipidemia in African Americans. PATIENTS AND METHODS: Conducted between July 19, 2004, and August 9, 2005, the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid End Points trial was a 20-week, open-label, noncomparative, multicenter trial of the efficacy and safety of single-pill amlodipine/atorvastatin in controlling elevated blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) in African Americans with concomitant HTN and dyslipidemia and either no additional risk factors, 1 or more cardiovascular risk factors, or coronary heart disease or a risk equivalent. Eight dosage strengths of single-pill amlodipine/atorvastatin were flexibly titrated. The primary efficacy assessment of the main trial was the percentage of patients who attained the LDL-C treatment goals of both the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National Cholesterol Education Program Adult Treatment Panel III. RESULTS: Of the 1170 African American patients screened, 501 were enrolled in the study and 499 received drug therapy. At end point, 236 (48.3%) of 489 patients reached both their BP and LDLC goals (vs 4 [0.8%] of 484 at baseline); 280 (56.8%) of 493 reached BP goals (vs 7 [1.4%] of 494 at baseline); and 361 (73.7%) of 490 reached LDL-C goals (vs 138 [28.5%] of 484 at baseline). Among the 499 patients receiving drug therapy, common treatment-related adverse events were peripheral edema (17 patients [3.4%]), headache (11 [2.2%]), myalgia (11 [2.2%]), and constipation (10 [2.0%]). CONCLUSION: Single-pill amlodipine/atorvastatin therapy was well tolerated and effectively targeted HTN and dyslipidemia in this population of African Americans who were at risk of cardiovascular disease.
Authors: Joel M Neutel; Michael Eaddy; Orsolya E Lunacsek; Craig Roberts; Linda Chen; Allison J Kean; James H Jackson Journal: J Clin Hypertens (Greenwich) Date: 2010-06 Impact factor: 3.738
Authors: Sara M Sarasua; Jiexiang Li; German T Hernandez; Keith C Ferdinand; Jonathan N Tobin; Kevin A Fiscella; Daniel W Jones; Angelo Sinopoli; Brent M Egan Journal: J Clin Hypertens (Greenwich) Date: 2017-05-07 Impact factor: 3.738
Authors: Duke Appiah; Pamela J Schreiner; Raegan W Durant; Catarina I Kiefe; Catherine Loria; Cora E Lewis; O Dale Williams; Sharina D Person; Stephen Sidney Journal: Ann Epidemiol Date: 2016-06-17 Impact factor: 6.996
Authors: Joel M Neutel; William H Bestermann; Eric M Dyess; Alan Graff; Attila Kursun; Santosh Sutradhar; Carla Yunis Journal: J Clin Hypertens (Greenwich) Date: 2009-01 Impact factor: 3.738
Authors: Keith C Ferdinand; John M Flack; Elijah Saunders; Ronald Victor; Karol Watson; Attila Kursun; Michael J Jamieson; Harry Shi Journal: J Clin Hypertens (Greenwich) Date: 2009-10 Impact factor: 3.738
Authors: Angharad N de Cates; Matthew R B Farr; Nicola Wright; Morag C Jarvis; Karen Rees; Shah Ebrahim; Mark D Huffman Journal: Cochrane Database Syst Rev Date: 2014-04-16